文献速递消化道肿瘤放疗姑息放疗与转移瘤

转移性胰腺导管腺癌原发肿瘤的MR引导自适应立体定向体部放疗(SBRT)用于疼痛控制:一项开放随机、多中心、平行组临床试验(MASPAC)

MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC).
PubMed 文献 · Radiat Oncol · 2022-01-25

MASPAC是一项前瞻性、双臂、随机对照、国际多中心研究,计划入组92例经组织学证实、初始8周标准全身化疗后至少疾病稳定的mPDAC患者,1:1随机分为MR引导自适应SBRT(5×6.6 Gy,80%等剂量线)联合标准化疗继续组与单纯标准化疗继续组,主要终点为每4周评估的平均累积疼痛指数。

要点

  • mPDAC患者上腹部及背部疼痛症状普遍,发生率80%。
  • 适形低剂量姑息放疗是成熟的局部治疗选择,但剂量强化放疗可能带来更好更持久的疼痛缓解。
  • SBRT可少分次给予高剂量,减少化疗间歇,但原发胰腺癌SBRT后疼痛控制的前瞻性数据非常有限。

核心结论

  • 作者假设mPDAC患者可从原发胰腺癌MR引导SBRT的局部治疗中获益,获得持久疼痛控制并具有有利的安全性特征,从而改善生活质量。

研究设计与样本

  • 前瞻性、双臂、随机对照、国际多中心研究,在德国和瑞士3个中心开展。
  • 计划入组92例经组织学证实的mPDAC患者,须在初始8周标准全身化疗后至少疾病稳定,按1:1随机分组。
  • 试验组A接受原发胰腺癌MR引导SBRT(5×6.6 Gy,80%等剂量线),之后继续标准全身化疗;对照组B仅继续标准全身化疗,不做SBRT。
  • 每日MR引导计划自适应旨在实现良好的靶区覆盖,同时最小化危及器官剂量。
  • 随访至少6个月、最长18个月;主要终点为每4周评估的平均累积疼痛指数(数字评定量表),直至死亡或研究结束。

主要发现

  • 原文未报告结果数据,本研究为在研试验方案。

关键数值与推荐

  • SBRT剂量为5×6.6 Gy,处方于80%等剂量线。
  • 入组条件为经组织学证实的mPDAC且初始8周标准全身化疗后至少疾病稳定。
  • 主要终点为平均累积疼痛指数,每4周用数字评定量表评估。
  • 随访时间至少6个月、最长18个月。
  • 试验注册号:德国临床试验注册(DRKS)DRKS00025801;ClinicalTrials.gov NCT05114213。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pain symptoms in the upper abdomen and back are prevalent in 80% of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), where the current standard treatment is a systemic therapy consisting of at least doublet-chemotherapy for fit patients. Palliative low-dose radiotherapy is a well-established local treatment option but there is some evidence for a better and longer pain response after a dose-intensified radiotherapy of the primary pancreatic cancer (pPCa). Stereotactic body radiation therapy (SBRT) can deliver high radiation doses in few fractions, therefore reducing chemotherapy-free intervals. However, prospective data on pain control after SBRT of pPCa is very limited. Therefore, we aim to investigate the impact of SBRT on pain control in patients with mPDAC in a prospective trial. METHODS: This is a prospective, double-arm, randomized controlled, international multicenter study testing the added benefit of MR-guided adaptive SBRT of the pPca embedded between standard of care-chemotherapy (SoC-CT) cycles for pain control and prevention of pain in patients with mPDAC. 92 patients with histologically proven mPDAC and at least stable disease after initial 8 weeks of SoC-CT will be eligible for the trial and 1:1 randomized in 3 centers in Germany and Switzerland to either experimental arm A, receiving MR-guided SBRT of the pPCa with 5 × 6.6 Gy at 80% isodose with continuation of SoC-CT thereafter, or control arm B, continuing SoC-CT without SBRT. Daily MR-guided plan adaptation intents to achieve good target coverage, while simultaneously minimizing dose to organs at risk. Patients will be followed up for minimum 6 and maximum of 18 months. The primary endpoint of the study is the "mean cumulative pain index" rated every 4 weeks until death or end of study using numeric rating scale. DISCUSSION: An adequate long-term control of pain symptoms in patients with mPDAC is an unmet clinical need. Despite improvements in systemic treatment, local complications due to pPCa remain a clinical challenge. We hypothesize that patients with mPDAC will benefit from a local treatment of the pPCa by MR-guided SBRT in terms of a durable pain control with a simultaneously favorable safe toxicity profile translating into an improvement of quality-of-life. TRIAL REGISTRATION: German Registry for Clinical Trials (DRKS): DRKS00025801. Meanwhile the study is also registered at ClinicalTrials.gov with the Identifier: NCT05114213.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Pavic M, Niyazi M, Wilke L, et al. MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC). Radiat Oncol. 2022. PMID: 35078490. doi:10.1186/s13014-022-01988-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。